Our logo and entire brand experience have been redesigned to better express Nuvisan’s dedication in partnering with our clients to support their drug discovery and development journey. Visitors to our redeveloped website will experience a streamlined and user-friendly architecture that offers seamless access to the essential information they need.  
 
These changes to our brand experience reflect a stronger understanding of why our clients value working with us. With over 40 years of experience in the life science industry, we remain focused on delivering what our clients need most. They choose to partner with us not only for our high-quality, end-to-end solutions and scientific expertise but moreover for the trust, transparency, flexibility and confidence that define our collaborations.  

 

When Nuvisan became part of global testing leader ALS in 2024, the joining of forces created one of the most advanced CRO/CDMOs in the biopharma industry, offering comprehensive, leading-edge solutions from drug discovery to post-commercialisation. Our rebranding speaks to how the new relationships and capabilities forged by this combination of teams can accelerate drug discovery and development to help get innovative medicines to the patients who need them. “This rebranding marks the beginning of an exciting new chapter for Nuvisan, and we look forward to strengthening our reputation as the partner of choice in bringing therapeutics to life,” said Rickard Olofsson, CEO, Nuvisan Group, and Executive General Manager Pharma, ALS.